- Home
- CANF vs BTX Comparison
CANF vs BTX Comparison
Compare CANF & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- BTX
- Stock Information
- Founded
- CANF 1994
- BTX N/A
- Country
- CANF Israel
- BTX United States
- Employees
- CANF N/A
- BTX N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- BTX
- Sector
- CANF Health Care
- BTX
- Exchange
- CANF Nasdaq
- BTX Nasdaq
- Market Cap
- CANF 7.9M
- BTX 1.3B
- IPO Year
- CANF N/A
- BTX N/A
- Fundamental
- Price
- CANF $1.12
- BTX $6.59
- Analyst Decision
- CANF Strong Buy
- BTX
- Analyst Count
- CANF 2
- BTX 0
- Target Price
- CANF $14.00
- BTX N/A
- AVG Volume (30 Days)
- CANF 444.9K
- BTX 605.7K
- Earning Date
- CANF 05-20-2025
- BTX 01-01-0001
- Dividend Yield
- CANF N/A
- BTX 6.47%
- EPS Growth
- CANF N/A
- BTX N/A
- EPS
- CANF N/A
- BTX N/A
- Revenue
- CANF $674,000.00
- BTX N/A
- Revenue This Year
- CANF $461.72
- BTX N/A
- Revenue Next Year
- CANF N/A
- BTX N/A
- P/E Ratio
- CANF N/A
- BTX N/A
- Revenue Growth
- CANF N/A
- BTX N/A
- 52 Week Low
- CANF $1.02
- BTX $5.10
- 52 Week High
- CANF $4.69
- BTX $8.31
- Technical
- Relative Strength Index (RSI)
- CANF 40.25
- BTX N/A
- Support Level
- CANF $1.02
- BTX N/A
- Resistance Level
- CANF $1.20
- BTX N/A
- Average True Range (ATR)
- CANF 0.06
- BTX 0.00
- MACD
- CANF 0.01
- BTX 0.00
- Stochastic Oscillator
- CANF 41.30
- BTX 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.